Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Parathyroid hormone: An anabolic treatment for osteoporosis
Autore:
Morley, P; Whitfield, JF; Willick, GE;
Indirizzi:
Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada Natl Res Council Canada Ottawa ON Canada K1A 0R6 tawa, ON K1A 0R6, Canada ParaTech Therapeut Inc, Ottawa, ON K1V 0Y3, Canada ParaTech Therapeut IncOttawa ON Canada K1V 0Y3 ttawa, ON K1V 0Y3, Canada
Titolo Testata:
CURRENT PHARMACEUTICAL DESIGN
fascicolo: 8, volume: 7, anno: 2001,
pagine: 671 - 687
SICI:
1381-6128(200105)7:8<671:PHAATF>2.0.ZU;2-F
Fonte:
ISI
Lingua:
ENG
Soggetto:
GROWTH-FACTOR-I; BONE-MINERAL DENSITY; GLUCOCORTICOID-INDUCED OSTEOPOROSIS; AGED OVARIECTOMIZED RATS; FEMORAL TRABECULAR BONE; ANTIRESORPTIVE AGENTS ESTROGEN; RECOMBINANT ESCHERICHIA-COLI; RANDOMIZED CONTROLLED TRIAL; CONTROLLED CLINICAL-TRIAL; RELEASE SODIUM-FLUORIDE;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
195
Recensione:
Indirizzi per estratti:
Indirizzo: Morley, P Natl Res Council Canada, Inst Biol Sci, Bldg M54,Montreal Rd Campus, Ottawa, ON K1A 0R6, Canada Natl Res Council Canada Bldg M54,Montreal Rd Campus Ottawa ON Canada K1A 0R6
Citazione:
P. Morley et al., "Parathyroid hormone: An anabolic treatment for osteoporosis", CUR PHARM D, 7(8), 2001, pp. 671-687

Abstract

Osteoporosis is a disease characterised by low bone mass, structural deterioration of bone and increased risk of fracture. The prevalence, and cost, of osteoporosis is increasing dramatically with our ageing population and the World Health Organization now considers it to be the second-leading healthcare problem. All currently approved therapies for osteoporosis leg., estrogen, bisphosphonates, calcitonin and selective estrogen receptor modulators) are anti-resorptive agents that act on osteoclasts to prevent further bone loss. A new class of bone anabolic agent capable of building mechanically strong new bone in patients with established osteoporosis is in development. While the parathyroid hormone (PTH) is classically considered to be a bone catabolic agent, when delivered intermittently at low doses PTH potently stimulates cortical and trabecular bone growth in animals humans. The native hPTH-(1-84) and its osteogenic fragment, hPTH-(1-34), have already entered Phase III clinical trials. Understanding the mechanism of PTH's osteogenic actions has led to the development of smaller PTH analogues which can also build mechanically normal bone in osteopenic rats. These new PTH analogues are promising candidates for treating osteoporosis in humans as they are as efficacious as hPTH-(1-84) and hPTH-(1-34), but there is evidence that they may have considerably less ability to induce hypercalcemia, the major side effect of PTH therapy. In addition to treating osteoporosis, PTHs may be used to promote fracture healing, to restore bone loss in immobilized patients, or following excessive glucocorticoid or prolonged spaceflight, and to treat psoriasis.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/01/20 alle ore 20:55:32